About this trial
Cardiovascular-renal-metabolic (CRM) syndrome is defined as a systemic disorder with a collection of related signs and symptoms attributable to the coexistence of multiple cardiovascular, renal and metabolic disease with a common underlying pathophysiology in one individual. Surveying this syndrome in a large population in Jordan aims at studying the risk factors, components and stages of the syndrome, thus helping early screening, diagnosing and treating disease and its risk factors.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adults (age 18 years and above).
Willing to sign an informed consent.
Disqualifiers
None.
Trial population
Consecutive individuals (N=10,000) visiting allocated medical laboratories in North, Center, and South sections of the country during public free blood testing campaigns planned in August 2024 to June 2025.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Prevalence of cardiovascular-renal-metabolic syndrome
1. CVD A. Coronary heart disease: Silent and clinical CAD (chronic stable coronary disease, acute coronary disease \[ST-elevation myocardial infarction and non-ST-elevation acute coronary syndrome\]. B. Heart failure. C. Atrial fibrillation. D. Stroke. E. Peripheral artery disease 2. Renal: chronic kidney disease 3. Metabolic: A. Obesity/ B. Diabetes mellitus (DM).
Secondary outcomes
Elevated levels of blood markers
Elevated level of lipoprotein (a) , homocysteine, high sensitivity C-Reactive Protein, insulin resistance, and Urine Creatinine/Albumin ratio.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Jordan Collaborating Cardiology Group
Lead sponsor
Cardiovascular Academy
Collaborator
The Association of Jordanian Medical Laboratory Specialists AJMLS
Collaborator
This trial is not recruiting at the moment. You can still explore other options: